Does Semaglutide Cause Delayed Wound Healing?
The evidence is conflicting, but the most recent high-quality research suggests semaglutide may be associated with increased wound complications in specific surgical populations, particularly non-diabetic patients using it for weight loss. However, in diabetic patients, the evidence paradoxically shows potential benefits or neutral effects on wound healing outcomes.
Key Evidence and Context
In Non-Diabetic Patients (Weight Loss Indication)
The most recent and directly relevant study found that preoperative semaglutide use in non-diabetic patients undergoing body contouring surgery was associated with significantly higher rates of wound dehiscence (5.19% vs 2.78%), delayed wound healing (2.58% vs 1.21%), and surgical site infections (5.37% vs 2.87%) compared to matched controls 1. This 2025 study specifically examined patients who had used semaglutide for ≥6 months before surgery, representing the growing population using GLP-1 receptor agonists solely for obesity management 1.
In Diabetic Patients (Diabetes/Mixed Indication)
Conversely, a large 2025 multicenter study of diabetic patients found that active perioperative GLP-1 RA prescriptions were associated with significantly reduced wound dehiscence (RR: 0.711) and no increase in infection rates 2. This suggests the metabolic benefits of GLP-1 RAs in diabetic patients may outweigh any potential wound healing concerns 2.
Mechanism and Biological Plausibility
GLP-1 receptor agonists, including semaglutide, cause delayed gastric emptying, which is a well-established pharmacodynamic effect 3. The FDA label explicitly states that "semaglutide causes a delay of gastric emptying" 3. However, this gastrointestinal effect does not directly explain wound healing complications.
Emerging evidence suggests GLP-1 receptors may actually promote wound healing through angiogenesis and improved keratinocyte migration 4, 5. A 2025 review noted that GLP-1 agonists have shown "promising anti-inflammatory effects and improvement in wound healing" in dermatologic contexts 5.
Clinical Decision-Making Algorithm
For Elective Surgery Planning:
1. Non-diabetic patients on semaglutide for weight loss:
- Consider holding semaglutide for at least 3 half-lives (approximately 3 weeks for semaglutide) before elective procedures with significant wound healing requirements 6, 7
- Enhanced preoperative counseling about increased wound complication risks is warranted 1
- The risk appears particularly elevated in body contouring and plastic surgery procedures 1
2. Diabetic patients on semaglutide:
- Consult with endocrinology regarding risks/benefits of continuing versus holding 7
- The cardiovascular and metabolic benefits may outweigh wound healing concerns in this population 2
- If held, arrange bridging diabetic therapy 7
- Evidence suggests continuation may actually reduce wound complications in diabetic patients 2
3. Fracture surgery considerations:
- One 2025 study found a modest increase in nonunion rates (5.4% vs 4.4%) in GLP-1 RA users, but this was offset by significantly reduced mortality (4.4% vs 8.0%) 8
- The mortality benefit likely outweighs the small increase in nonunion risk 8
Important Caveats and Pitfalls
The evidence quality is limited by:
- Most wound healing data comes from retrospective studies, not randomized trials 1, 8, 2
- The mechanism linking GLP-1 RAs to wound complications remains unclear and may be confounded by nutritional status, weight loss velocity, or patient selection 1, 4
- Guidelines on perioperative management remain in flux, with recent 2025 consensus statements still emphasizing uncertainty 6
Common pitfall: Assuming all GLP-1 RA users have the same risk profile. The indication (diabetes vs. obesity), dose (higher doses for weight loss), and surgical type significantly modify risk 9, 7, 1.
Critical consideration: While semaglutide may delay gastric emptying and theoretically impact perioperative aspiration risk 6, 3, this is a separate concern from wound healing and should not be conflated.